Select Conferences

Court Determines that University of Pittsburgh and Artecel have Sole Rights to Adipose-Derived Stem Cell Patent
Cytori and UC Lose rights to adipose-derived stem cells; business agreements and activity under other patents likely affected.

BioTime and Embryome Sciences Launch Embryome.com and the International Embryome Initiative
The international collaboration with scientists around the world will create the first systematic map of all the cell types derived from human embryonic stem cells.

454 Sequencing at the Forefront of Bone Marrow and Stem Cell Therapy Research
Roche Genome Sequencer FLX System will create new opportunities for HLA research at the Blood Centre Linz, Austria.

Ronin Provides Alternate Pathway to Pristine Embryonic Stem Cells
The protein Ronin maintains embryonic stem cells in their undifferentiated state and plays roles in genesis of embryos and their development, researchers say.

Pluristem Certified as a Good Manufacturing Practices Site for the Manufacture of PLX cells for its Clinical Trials
The GMP certification has been approved for the purpose of manufacturing PLX cells which will be shipped to the EU for use in the Company’s upcoming clinical trials.

High Content Image Analysis using a Laser Scanning Microplate Cytometer
TTP Labtech

Microscope-based high-content instruments offer high optical resolution, however, the limited field of view afforded by their objective lenses can mean lengthy read times for some assays, especially where multiple image capture per well is required. Wherever possible, only a small percentage of the total number of cells present in a test well are analysed to keep plate read times at a minimum, which may not always be ideal. Microplate laser- scanning cytometers, such as TTP LabTech’s Acumen® eX3

Stem Cell Derived Human Neurons in CNS Drug Discovery
Scottish Biomedical

Central nervous system disorders affect many people worldwide. To increase the quality and number of drugs available for treatments of CNS disorders such as Alzheimer’s, schizophrenia and anxiety, the success rate of CNS drug discovery programmes must be improved. The challenge in drug discovery is to develop more relevant assay systems to identify lead compounds for further development. Cell based screening assays currently used for CNS drug development involve primary cells or commercially

Regulatory Services Business Development
Recruiter: VRS Regulatory
Central Scotland, UK

Team Leader, Bioanalysis
Biodynamics Research Limited
Rushden, Northants, UK

Regulatory Toxicologist
VRS Regulatory
Cheshire, UK

Metabonomics Scientist
Nestlé Research Center
Lausanne, Switzerland

NanoBio Commercialisation Manager
Cenamps
Newcastle Upon Tyne, UK

Laboratory Technician
Peptide Protein Research
UK

Drug Discovery & Development of Innovative Therapeutics, Boston, MA, USA
04 August 2008 - 07 August 2008

Practical, Actionable Ideas for Accelerating Discovery and Early Development. The Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress is the ONLY international event that compares applications of translational medicine and transforming technologies across multiple therapeutic areas to help you find new ways to achieve POC quickly. View the full program agenda online at www.drugdisc.com.

Stem Cells Europe, Amsterdam, The Netherlands
01 September 2008 - 03 September 2008

Select Biosciences inaugural Stem Cells Europe Conference and Exhibition. Confirmed Speakers include Stephen Minger of Kings College, Bernard Siegel of Genetics Policy Institute and Fergus McKenzie of ITI Life Sciences.

The European Congress on Anti-Aging and Aesthetic Medicine, Düsseldorf, Germany
11 September 2008 - 14 September 2008

The European Congress on Anti-Aging and Aesthetic Medicine (ECAAAM) will take place on 11-14 September in Düsseldorf, Germany. We invite you to join this fast growing medical specialty and network with the most influential educators and industrialists from around the world.
  

Cancer Stem Cells - Emerging Therapeutic, Diagnostic and Market Opportunities
Published April 2007

The last decade has seen the emergence of a new paradigm in the therapeutic strategies which may be available to target cancer. This is based on the existence of so called Cancer Stem Cells (CSCs), found in small populations within the bulk of normal proliferating cancer cells, in tumours. Many scientists believe that CSCs are responsible for the development and spread of cancer and explain why the disease is resistant to many conventional treatments and able to reestablish itself after therapy.

Tissue Engineering & Stem Cell Technology Report 2007
Published Febraury 2007

The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.